ArticleAmerican journal of translational research2026
Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the effect of 4-week and 6-week transarterial chemoembolization (TACE) intervals on tumor response and liver function in patients with unresectable hepatocellular carcinoma (HCC) receiving TACE plus programmed death-1 (PD-1) inhibitor combination therapy.
methodsA total of 186 patients with unresectable HCC who underwent TACE combined with PD-1 inhibitor therapy were enrolled in this retrospective study. All patients were categorized into two groups according to TACE treatment intervals: the 4-week interval group (n=92) and the 6-week interval group (n=94). Baseline demographic and clinical data were collected for all participants. Hepatic and renal function indicators, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB), creatinine (Cr), and blood urea nitrogen (BUN), as well as serum tumor markers consisting of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), were detected at baseline and one month after treatment initiation. Tumor response was evaluated at three months post-treatment based on the RECIST 1.1, and the objective response rate (ORR) and disease control rate (DCR) were calculated accordingly. Treatment-related adverse events (AEs) were documented and graded in accordance with the CTCAE v5.0. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of treatment to death or disease progression, with continuous follow-up until the study endpoint.
resultsThe 186 enrolled patients were well-balanced in baseline clinicopathologic characteristics between the two groups. Compared to the 6-week group, the 4-week group achieved significantly higher ORR (35.87% vs. 22.34%, P=0.042) and DCR (81.52% vs. 67.02%, P=0.024), a more substantial reduction in AFP level, and markedly prolonged median OS and PFS (all P<0.001). Nevertheless, the 4-week group presented significantly elevated ALT levels (P=0.001) and decreased ALB levels (P=0.012) at one month post-treatment. Multivariate Cox regression analysis identified the 4-week interval as an independent favorable prognostic factor for OS (HR=0.692, 95% CI 0.498-0.961, P=0.029). The overall incidence of AEs was comparable between the two groups.
conclusionFor patients with unresectable HCC treated with TACE combined with PD-1 inhibitors, a 4-week TACE interval yielded superior tumor response and survival benefits with acceptable hepatic safety compared to a 6-week interval, which supports the 4-week interval as an optimal clinical treatment schedule.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.